Us Respiratory Durable Medical Equipment Market Report: Market Size & Forecast 2026

The U.S. respiratory DME market covers a wide range of equipment designed to deliver oxygen therapy, assist with breathing during sleep, and manage chronic respiratory conditions in home, institutional, and acute care settings. Oxygen therapy equipment, sleep apnea devices such as CPAP and BiPAP machines, and mechanical ventilators represent the largest segments, with oxygen concentrators alone accounting for a substantial share of total revenue.

• •The market addresses conditions including COPD, asthma, obstructive sleep apnea, cystic fibrosis, and respiratory failure
• •Medicare and Medicaid reimbursement programs play a central role in market accessibility and pricing dynamics
• •Home-based respiratory care has grown significantly as payers and providers seek lower-cost alternatives to hospitalization

The market's expansion is underpinned by demographic shifts, with the U.S. population of adults aged 65 and older projected to reach over 70 million by 2030, a cohort that carries a higher burden of respiratory disease. Rising incidence of COPD and sleep apnea, exacerbated by obesity and environmental factors, has increased demand for both diagnostic and therapeutic respiratory equipment. Additionally, the shift toward value-based care and hospital-at-home programs has accelerated the adoption of remote patient monitoring and connected respiratory devices.

• •Over 16 million Americans are diagnosed with COPD, and an estimated 39 million have been diagnosed with sleep apnea, with millions more undiagnosed
• •Advancements in portable oxygen concentrators and battery-operated ventilators have expanded use cases beyond stationary home settings
• •FDA clearances and CMS coverage decisions for telehealth-connected respiratory devices have broadened reimbursement eligibility

The market is broadly segmented by product type, end user, and distribution channel. Product categories include oxygen equipment, positive airway pressure devices, ventilators, nebulizers, and humidifiers. By end user, hospitals and home care settings dominate, with home care gaining share due to cost pressures and patient preference. Regionally, the U.S. South and Midwest tend to have higher prevalence of COPD linked to smoking rates and occupational exposures, while the aging Northeast drives demand for sleep apnea and home oxygen services.

• •Oxygen therapy equipment holds the largest product segment share, with portable concentrators representing the fastest-growing subcategory
• •Home care settings are projected to outpace hospital demand through 2030 as home-based treatment models expand
• •States with larger elderly populations and higher rates of respiratory illness, such as West Virginia, Kentucky, and Alabama, represent concentrated regional demand

What are the recent trends and outlook?

Looking ahead, the U.S. respiratory DME market is expected to continue its upward trajectory, supported by ongoing device innovation, an aging and medically complex population, and sustained policy emphasis on reducing healthcare costs through home and community-based services. Integration of artificial intelligence and connected health platforms into respiratory devices is expected to enhance patient adherence and enable proactive clinical interventions. However, market participants face headwinds from potential reimbursement rate pressures, supply chain volatility, and regulatory scrutiny around device safety and marketing practices.

• •Smart CPAP and oxygen concentrator devices with mobile app connectivity and cloud-based data analytics are expanding patient engagement
• •CMS and private payers are piloting bundled payment models for home respiratory care that could reshape provider economics
• •Portable, lightweight, and battery-efficient respiratory equipment remains a priority for manufacturers catering to active patient populations